Amnovis CEO on 100K Implants, Multi-Material 3D Printing, and Redefining Manufacturing

In a recent episode of the Additive Insight podcast, Amnovis CEO Ruben Wauthle shared insights into the company's remarkable journey and ambitious plans for the future of additive manufacturing.

From Medical Pioneer to Industrial Player

Founded five years ago, Amnovis has established itself as a leading manufacturing production service for the medical sector, specializing in spinal, orthopedic, and craniomaxillofacial (CMF) implants. The company recently reached a major milestone: delivering its 100,000th 3D printed implant.

"We want to redefine the state of the art in additive manufacturing," Wauthle stated in the interview. This vision drives the company's expansion beyond medical devices into industrial markets.

Scaling Production to Meet Demand

The numbers tell a compelling story. In 2025 alone, Amnovis shipped over 50,000 implants—essentially half of its five-year total in just one year. Currently, the company produces approximately 60,000 implants per year, demonstrating the rapid scale-up of its manufacturing operations.

This growth has been fueled by Amnovis's innovative heat treatment-free titanium 3D printing process, which has reportedly shortened time-to-market for medical devices while enabling cost savings for manufacturers adopting 3D printed solutions.

The Multi-Material Future

Looking ahead, Amnovis is investing heavily in R&D to push the boundaries of metal powder bed fusion technology. The company is working on printing with multiple materials, a capability that could unlock new applications in both medical and industrial sectors.

Multi-material metal 3D printing would allow for the creation of parts with graded properties—combining different metals within a single build to optimize strength, weight, and functionality. This represents the next frontier in additive manufacturing.

What This Means for the Industry

Amnovis's trajectory illustrates several key trends in 3D printing:

• Medical AM is maturing—companies are moving from prototyping to full-scale production
• Production volumes are scaling—60,000+ implants annually represents real manufacturing at scale
• Industrial expansion—medical-focused AM companies are eyeing industrial applications
• Process innovation matters—heat treatment-free processes provide competitive advantages

As Amnovis continues to scale and push into new territories, the company represents a model for how additive manufacturing can transition from a prototyping technology to a full-scale production solution.